跳至主導覽 跳至搜尋 跳過主要內容

Psilocybin for end-of-life anxiety symptoms: A systematic review and meta-analysis

  • Chia Ling Yu
  • , Fu Chi Yang
  • , Szu Nian Yang
  • , Ping Tao Tseng
  • , Brendon Stubbs
  • , Ta Chuan Yeh
  • , Chih Wei Hsu
  • , Dian Jeng Li*
  • , Chih Sung Liang*
  • *此作品的通信作者
  • Chang Gung Memorial Hospital
  • Triservice General Hospital Taiwan
  • National Defense Medical University
  • Taichung Armed Forces General Hospital
  • National Yang Ming Chiao Tung University
  • WinShine Clinics in Specialty of Psychiatry
  • South London and Maudsley NHS Foundation Trust
  • King's College London
  • Anglia Ruskin University
  • Kaohsiung Municipal Kai-Syuan Psychiatric Hospital
  • Meiho University

研究成果: 期刊稿件 › 文章 › 同儕審查

52 引文 斯高帕斯(Scopus)

摘要

Objective To systematically examine the effectiveness and tolerability of psilocybin for treating end-of-life anxiety symptoms. Methods The Medline, Embase, CENTRAL, and PsycINFO databases were searched up to November 25, 2020. We enrolled clinical trials investigating psilocybin for treating end-of-life anxiety symptoms. Meta-analysis was conducted using random-effects model. Results Overall, five studies were included, revealing that psilocybin was superior to the placebo in treating state anxiety at 1 day (Hedges’ g,-0.70; 95% confidence interval,-1.01 to-0.39) and 2 weeks (-1.03;-1.47 to-0.60) after treatment. Psilocybin was more effective than placebo in treating trait anxiety at 1 day (-0.71;-1.15 to-0.26), 2 weeks (-1.08;-1.80 to-0.36), and 6 months (-0.84;-1.37 to-0.30) after treatment. Psilocybin was associated with transient elevation in systolic (19.00; 13.58–24.41 mm Hg) and diastolic (8.66; 5.18–12.15 mm Hg) blood pressure compared with placebo. The differences between psilocybin and placebo groups with regard to all-cause discontinuation, serious adverse events, and heart rates were nonsignificant. Conclusion Psilocybin-assisted therapy could ameliorate end-of-life anxiety symptoms without serious adverse events. Because of the small sample sizes of the included studies and high heterogeneity on long-term outcomes, future randomized controlled trials with large sample sizes are needed.

原文英語
頁(從 - 到)958-967
頁數10
期刊Psychiatry Investigation
卷18
發行號10
DOIs
出版品狀態已出版 - 10 2021

文獻附註

Publisher Copyright:
© 2021 Korean Neuropsychiatric Association.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Psilocybin for end-of-life anxiety symptoms: A systematic review and meta-analysis」主題。共同形成了獨特的指紋。

引用此